Maz51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo

被引:54
作者
Kirkin, V
Thiele, W
Baumann, P
Mazitschek, R
Rohde, K
Fellbrich, G
Weich, H
Waltenberger, J
Giannis, A
Sleeman, JP
机构
[1] Forschungszentrum Karlsruhe, Inst Genet & Toxikol, D-76021 Karlsruhe, Germany
[2] Univ Leipzig, Inst Organ Chem, Leipzig, Germany
[3] Univ Ulm Klinikum, Innere Med Abt 2, Ulm, Germany
[4] German Res Ctr Biotechnol, Dept Gene Regulat & Gene Differentat, Div Mol Biotechnol, Braunschweig, Germany
关键词
indolinone; VEGFR-3; lymphangiogenesis; angiogenesis; inhibitor;
D O I
10.1002/ijc.20509
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have recently described MAZ51, an indolinone that blocks the ligand-induced autophosphorylation of VEGFR-3, a receptor tyrosine kinase that plays a central role in the regulation of lymphangiogenesis. Here we show that MAZ51 is able to block the proliferation of VEGFR-3-expressing human endothelial cells and is less potently able to induce their apoptosis. MAZ51 also inhibits the proliferation and induces the apoptosis of a variety of non-VEGFR-3-expressing tumor cell lines. These data suggest that MAZ51 blocks the activity of tyrosine kinases in addition to VEGFR-3. In vivo, MAZ51 significantly inhibits the growth of rat mammary carcinomas. These data establish MAZ51 as a compound with antitumor properties that inhibits tumor growth directly and also indirectly by interfering with tumor-host interactions. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:986 / 993
页数:8
相关论文
共 31 条
[1]   Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4) [J].
Achen, MG ;
Jeltsch, M ;
Kukk, E ;
Mäkinen, T ;
Vitali, A ;
Wilks, AF ;
Alitalo, K ;
Stacker, SA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (02) :548-553
[2]   Protein kinases - the major drug targets of the twenty-first century? [J].
Cohen, P .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (04) :309-315
[3]   Characterization of murine Flt4 ligand VEGF-C [J].
Fitz, LJ ;
Morris, JC ;
Towler, P ;
Long, A ;
Burgess, P ;
Greco, R ;
Wang, J ;
Gassaway, R ;
Nickbarg, E ;
Kovacic, S ;
Ciarletta, A ;
Giannotti, J ;
Finnerty, H ;
Zollner, R ;
Beier, DR ;
Leak, LV ;
Turner, KJ ;
Wood, CR .
ONCOGENE, 1997, 15 (05) :613-618
[4]   Role of angiogenesis in tumor growth and metastasis [J].
Folkman, J .
SEMINARS IN ONCOLOGY, 2002, 29 (06) :15-18
[5]   Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling [J].
He, YL ;
Kozaki, KI ;
Karpanen, T ;
Koshikawa, K ;
Yla-Herttuala, S ;
Takahashi, T ;
Alitalo, K .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (11) :819-825
[6]   Role of lymphangiogenic factors in tumor metastasis [J].
He, YL ;
Karpanen, T ;
Alitalo, K .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2004, 1654 (01) :3-12
[7]   Hyperplasia of lymphatic vessels in VEGF-C transgenic mice [J].
Jeltsch, M ;
Kaipainen, A ;
Joukov, V ;
Meng, XJ ;
Lakso, M ;
Rauvala, H ;
Swartz, M ;
Fukumura, D ;
Jain, RK ;
Alitalo, K .
SCIENCE, 1997, 276 (5317) :1423-1425
[8]  
Joukov V, 1996, EMBO J, V15, P290
[9]   Vascular growth factors and lymphangiogenesis [J].
Jussila, L ;
Alitalo, K .
PHYSIOLOGICAL REVIEWS, 2002, 82 (03) :673-700
[10]   EXPRESSION OF THE FMS-LIKE TYROSINE KINASE-4 GENE BECOMES RESTRICTED TO LYMPHATIC ENDOTHELIUM DURING DEVELOPMENT [J].
KAIPAINEN, A ;
KORHONEN, J ;
MUSTONEN, T ;
VANHINSBERGH, VWM ;
FANG, GH ;
DUMONT, D ;
BREITMAN, M ;
ALITALO, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (08) :3566-3570